These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 29502954)

  • 21. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
    Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.
    Trifirò P; Cappa A; Brambillasca S; Botrugno OA; Cera MR; Zuffo RD; Dessanti P; Meroni G; Thaler F; Villa M; Minucci S; Mercurio C; Varasi M; Vianello P
    Future Med Chem; 2017 Jul; 9(11):1161-1174. PubMed ID: 28722470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [ORY-1001 inhibits glioblastoma cell growth by downregulating the Notch/HES1 pathway
    Yang H; Xiang Y; Tan T; Lei Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 Aug; 44(8):1620-1630. PubMed ID: 39276059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation.
    Li ZR; Suo FZ; Guo YJ; Cheng HF; Niu SH; Shen DD; Zhao LJ; Liu ZZ; Maa M; Yu B; Zheng YC; Liu HM
    Bioorg Chem; 2020 Apr; 97():103648. PubMed ID: 32065882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.
    Sareddy GR; Viswanadhapalli S; Surapaneni P; Suzuki T; Brenner A; Vadlamudi RK
    Oncogene; 2017 Apr; 36(17):2423-2434. PubMed ID: 27893719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LSD1: biologic roles and therapeutic targeting.
    Maiques-Diaz A; Somervaille TC
    Epigenomics; 2016 Aug; 8(8):1103-16. PubMed ID: 27479862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.
    Sonnemann J; Zimmermann M; Marx C; Ebert F; Becker S; Lauterjung ML; Beck JF
    Br J Haematol; 2018 Nov; 183(3):494-497. PubMed ID: 29205263
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML.
    Nicosia L; Boffo FL; Ceccacci E; Conforti F; Pallavicini I; Bedin F; Ravasio R; Massignani E; Somervaille TCP; Minucci S; Bonaldi T
    Oncogene; 2022 Feb; 41(6):878-894. PubMed ID: 34862459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of natural product-like spirooxindole derivatives as highly potent and selective LSD1/KDM1A inhibitors for AML treatment.
    Yang C; Fang Y; Luo X; Teng D; Liu Z; Zhou Y; Liao G
    Bioorg Chem; 2022 Mar; 120():105596. PubMed ID: 35051709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.
    Cavalcanti F; Gonzalez-Rey E; Delgado M; Falo CP; Mestre L; Guaza C; O'Valle F; Lufino MMP; Xaus J; Mascaró C; Lunardi S; Sacilotto N; Dessanti P; Rotllant D; Navarro X; Herrando-Grabulosa M; Buesa C; Maes T
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy.
    Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable
    Mascaró C; Ortega A; Carceller E; Ruiz Rodriguez R; Ciceri F; Lunardi S; Yu L; Hilbert M; Maes T
    J Biol Chem; 2019 May; 294(20):8311-8322. PubMed ID: 30804215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies.
    Tayari MM; Santos HGD; Kwon D; Bradley TJ; Thomassen A; Chen C; Dinh Y; Perez A; Zelent A; Morey L; Cimmino L; Shiekhattar R; Swords RT; Watts JM
    Clin Cancer Res; 2021 Apr; 27(7):1893-1903. PubMed ID: 33495312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
    Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
    Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ORY-1001, a KDM1A inhibitor, inhibits proliferation, and promotes apoptosis of triple negative breast cancer cells by inactivating androgen receptor.
    Wang T; Zhang F; Sun F
    Drug Dev Res; 2022 Feb; 83(1):208-216. PubMed ID: 34347904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.